Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance

BMJ. 2014 Jul 17:349:g4356. doi: 10.1136/bmj.g4356.

Authors

Silvia Rabar¹, Martin Harker², Norma O'Flynn², Anthony S Wierzbicki³; Guideline Development Group

Collaborators

Guideline Development Group:
Anthony Wierzbicki, Rajai Ahmad, Lindsay Banks, Liz Clark, Martin Duerden, Eleanor Grey, Michael Khan, Emma McGowan, Dermot Neely, Nadeem Qureshi, Alan Rees, Angela Cooper, Lina Gulhane, Martin Harker, Norma O'Flynn, Silvia Rabar

Affiliations

¹ National Clinical Guideline Centre, Royal College of Physicians, London NW1 4LE, UK silvia.rabar@rcplondon.ac.uk.
² National Clinical Guideline Centre, Royal College of Physicians, London NW1 4LE, UK.
³ Guy's and St Thomas' Hospitals, London, UK.

PMID: 25035388
DOI: 10.1136/bmj.g4356

No abstract available

MeSH terms

Anion Exchange Resins / administration & dosage
Cardiovascular Diseases / blood
Cardiovascular Diseases / prevention & control*
Diabetes Complications
Diet
Fatty Acids, Omega-3 / administration & dosage
Fibric Acids / administration & dosage
Glomerular Filtration Rate
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Hyperlipidemias / drug therapy
Hypolipidemic Agents / administration & dosage
Lipids / blood*
Nicotinic Acids / administration & dosage
Practice Guidelines as Topic
Primary Prevention
Renal Insufficiency, Chronic / complications
Risk Assessment*
Secondary Prevention

Substances

Anion Exchange Resins
Fatty Acids, Omega-3
Fibric Acids
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypolipidemic Agents
Lipids
Nicotinic Acids